Dr. Wright’s consulting work has included analysis of mergers, vertical restraints, price fixing claims, monopolization, damages, price discrimination, and intellectual property matters.
Washington, DC
Matthew Wright’s consulting work has included analysis of mergers, vertical restraints, price fixing claims, monopolization, damages, price discrimination, and intellectual property matters. He has experience in a wide range of industries, including pharmaceuticals, freight transportation, tobacco, casinos, music rights, food industries, electronic equipment, business services, various branded consumer goods.
Dr. Wright has provided economic testimony on antitrust liability, damages, Robinson-Patman, and intellectual property matters. He has also represented clients before the U.S. Department of Justice, the Federal Trade Commission, and the European Commission. Dr. Wright co-edited and contributed to the American Bar Association volume titled Antitrust Law and Economics of Product Distribution.
Before joining Secretariat, Dr. Wright served seven years as an economist with the U.S. Department of Justice’s Antitrust Division, where he worked on many mergers, civil non-merger matters, and price-fixing investigations. Dr. Wright also served as a technical advisor to six foreign governments on competition policy.
Statistics Tools Chart A Path For AI Use In Expert Testimony
As AI and machine learning tools become more common in expert workflows, courts are increasingly scrutinizing their use under Federal Rule of Evidence 702. In The Risks and a Path Forward for AI and Machine Learning Tools in Expert Testimony, we examine recent cases where AI-assisted opinions were excluded due to concerns about reliability, transparency, and expert understanding.
In this GIR article, Stephen Millington and Dominique Dondelinger examine the growing fraud risks facing the Gulf region amid rapid economic expansion and transformative Vision 2030 strategies.
Public Cos. Must Heed Disclosure Risks Amid Trade Chaos
Ongoing uncertainties caused by the trade war and President Donald Trump’s evolving stance on tariffs and trade restrictions, including sanctions and export controls, have exponentially escalated financial reporting pressures on public companies. In this article, we discuss the key financial reporting and disclosure risks, as well as takeaways, for public companies as they navigate significant market instability in international trade.